MHRA approves Astellas’ Vyloy combination for gastric cancer
Most cases go undetected until an advanced stage, as the disease rarely causes early symptoms
Read Moreby PharmaTimes | Aug 23, 2024 | News | 0
Most cases go undetected until an advanced stage, as the disease rarely causes early symptoms
Read Moreby Lucy Parsons | Jan 18, 2021 | News | 0
Approval is based on results from the Phase III DESTINY-Gastric01 trial
Read Moreby Lucy Parsons | Oct 28, 2020 | News | 0
FDA action date for regulatory decision set during first quarter of 2021
Read Moreby Lucy Parsons | Aug 12, 2020 | News | 0
Topline results published from CheckMate-649 and CheckMate-577 studies
Read Moreby Anna Smith | May 7, 2019 | News | 0
The test “advances Roche’s commitment to personalised healthcare”.
Read Moreby Anna Smith | May 2, 2019 | News | 0
Approximately one in five breast and gastric cancers are HER2-positive.
Read Moreby Selina McKee | Dec 11, 2017 | News | 0
Eli Lilly’s Cyramza has hit its primary goal in a late-stage study showing extended progression-free survival in patients with gastric cancer, but the drug failed to improve overall survival, a secondary endpoint.
Read Moreby Selina McKee | Nov 29, 2017 | News | 0
Merck and Pfizer have revealed that a Phase III trial assessing avelumab in patients with gastric cancer after two prior therapeutic regimens failed to hit its primary target of showing an improvement in survival.
Read Moreby Selina McKee | Nov 20, 2017 | News | 0
European regulators have approved the first biosimilar of Roche’s blockbuster biologic Herceptin, issuing a green light for Samsung Bioepis’ Ontruzant.
Read Moreby Selina McKee | Oct 4, 2016 | News | 0
European regulators have agreed to review Samsung Bioepis’ application to market SB3, a biosimilar of Roche’s cancer drug Herceptin.
Read Moreby Selina McKee | May 19, 2016 | News | 0
AstraZeneca’s Lynparza has failed to hit targets in a Phase III trial assessing its effect on survival in patients with advanced gastric cancer.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
